Baltimore Washington Financial Advisors Inc. Has $29.38 Million Stock Holdings in Stryker Corporation $SYK

Baltimore Washington Financial Advisors Inc. lifted its position in Stryker Corporation (NYSE:SYK) by 6.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 74,261 shares of the medical technology company’s stock after buying an additional 4,602 shares during the quarter. Stryker comprises approximately 1.4% of Baltimore Washington Financial Advisors Inc.’s holdings, making the stock its 27th largest position. Baltimore Washington Financial Advisors Inc.’s holdings in Stryker were worth $29,380,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Consolidated Portfolio Review Corp boosted its holdings in Stryker by 4.2% during the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after acquiring an additional 26 shares during the period. Princeton Global Asset Management LLC increased its stake in shares of Stryker by 16.9% in the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after purchasing an additional 26 shares during the period. Sunflower Bank N.A. lifted its position in shares of Stryker by 4.0% during the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock worth $275,000 after purchasing an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC boosted its stake in Stryker by 3.2% during the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after purchasing an additional 27 shares during the period. Finally, Sachetta LLC grew its holdings in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SYK shares. Barclays upped their price target on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Stryker in a research note on Tuesday. Sanford C. Bernstein reissued an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Truist Financial raised their price target on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research report on Friday, November 14th. Finally, Evercore ISI cut their price objective on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a research report on Friday, October 31st. Thirteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $434.37.

Stryker Stock Performance

NYSE:SYK opened at $372.04 on Thursday. The firm has a market capitalization of $142.28 billion, a PE ratio of 49.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The firm has a 50-day moving average price of $369.13 and a 200 day moving average price of $380.49.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. During the same period in the prior year, the company posted $2.87 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the sale, the chief financial officer owned 6,694 shares in the company, valued at $2,449,200.72. This represents a 2.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 522,118 shares of company stock worth $185,381,932 over the last three months. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.